User login
Key clinical point: Compared with the general population, patients with psoriatic arthritis (PsA) had a higher prevalence of cardiovascular events (CVE) and cardiovascular risk factors (CVRF) in real-life conditions, with CVRF being higher in patients with PsA as estimated using either SCORE-PsA or QRISK2-PsA cardiovascular risk algorithms.
Major finding: Patients with PsA vs. controls had a higher prevalence of CVE (8.7% vs. 4.1%; P = .03) and CVRF, such as high body mass index (26.6 vs. 25.2; P = .001), triglyceride level (1.24 vs. 1.06; P = .001) and hypertension (34.4% vs. 26.3%; P = .03). The proportion of patients with PsA who were estimated to have a very high CVRF (≥10%) increased when SCORE (25.4% to 27.4%) and QRISK2 (44.9% to 53.2%) equations considered the additional risk attributable to PsA.
Study details: Findings are from an observational, cross-sectional, case-control study including 207 patients with PsA and 414 matched controls.
Disclosures: This study did not report any funding. The authors declared no conflicts of interest.
Source: Degboe Y et al. Increased cardiovascular risk in psoriatic arthritis: results from a case-control monocentric study. Front Med. 2022;8:785719 (May 19). Doi: 10.3389/fmed.2022.785719
Key clinical point: Compared with the general population, patients with psoriatic arthritis (PsA) had a higher prevalence of cardiovascular events (CVE) and cardiovascular risk factors (CVRF) in real-life conditions, with CVRF being higher in patients with PsA as estimated using either SCORE-PsA or QRISK2-PsA cardiovascular risk algorithms.
Major finding: Patients with PsA vs. controls had a higher prevalence of CVE (8.7% vs. 4.1%; P = .03) and CVRF, such as high body mass index (26.6 vs. 25.2; P = .001), triglyceride level (1.24 vs. 1.06; P = .001) and hypertension (34.4% vs. 26.3%; P = .03). The proportion of patients with PsA who were estimated to have a very high CVRF (≥10%) increased when SCORE (25.4% to 27.4%) and QRISK2 (44.9% to 53.2%) equations considered the additional risk attributable to PsA.
Study details: Findings are from an observational, cross-sectional, case-control study including 207 patients with PsA and 414 matched controls.
Disclosures: This study did not report any funding. The authors declared no conflicts of interest.
Source: Degboe Y et al. Increased cardiovascular risk in psoriatic arthritis: results from a case-control monocentric study. Front Med. 2022;8:785719 (May 19). Doi: 10.3389/fmed.2022.785719
Key clinical point: Compared with the general population, patients with psoriatic arthritis (PsA) had a higher prevalence of cardiovascular events (CVE) and cardiovascular risk factors (CVRF) in real-life conditions, with CVRF being higher in patients with PsA as estimated using either SCORE-PsA or QRISK2-PsA cardiovascular risk algorithms.
Major finding: Patients with PsA vs. controls had a higher prevalence of CVE (8.7% vs. 4.1%; P = .03) and CVRF, such as high body mass index (26.6 vs. 25.2; P = .001), triglyceride level (1.24 vs. 1.06; P = .001) and hypertension (34.4% vs. 26.3%; P = .03). The proportion of patients with PsA who were estimated to have a very high CVRF (≥10%) increased when SCORE (25.4% to 27.4%) and QRISK2 (44.9% to 53.2%) equations considered the additional risk attributable to PsA.
Study details: Findings are from an observational, cross-sectional, case-control study including 207 patients with PsA and 414 matched controls.
Disclosures: This study did not report any funding. The authors declared no conflicts of interest.
Source: Degboe Y et al. Increased cardiovascular risk in psoriatic arthritis: results from a case-control monocentric study. Front Med. 2022;8:785719 (May 19). Doi: 10.3389/fmed.2022.785719